Core Viewpoint - Jin Hai Medical Technology (02225) experienced a significant decline in stock price, dropping over 36% during trading, with an intraday drop exceeding 65% [1] Group 1: Stock Performance - As of the report, the stock price fell by 36.11%, trading at HKD 1.15, with a trading volume of HKD 161 million [1] - The stock's decline is attributed to the announcement of a subscription agreement with three independent private investors [1] Group 2: Subscription Agreement Details - The company entered into three subscription agreements to issue a total of 120 million shares at a subscription price of HKD 1.35 per share [1] - The subscription price represents a discount of approximately 17.68% compared to the closing price of HKD 1.64 on the date of the agreement [1] - The net proceeds from the subscription, after deducting applicable costs and expenses, are expected to be around HKD 160 million, with a net issuance price of approximately HKD 1.34 per share [1] Group 3: Use of Proceeds - The company plans to use the proceeds from the subscription for potential acquisitions in the healthcare sector, funding for healthcare-related projects, research and development expenses, and general working capital [1]
今海医疗科技盘中跌超36% 公司近期拟折让约17.68%发行合共1.2亿股认购股份